Jasem Albarrak

Dr. Jasem Albarrak


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JAJasem Albarrak
Jasem Albarrak
HAHumaid O Al-Shamsi
Humaid O Al-Shamsi
The burden of hepatocellular carcinoma (HCC) is on the rise in the Gulf region, with most patients being diagnosed in the intermediate or advanced stages. Surgery is a treatment option for only a few, and the majority of patients receive either locoregional treatment (percutaneous ethanol injection, radiofrequency ablation, transarterial chemoembolization [TACE], radioembolization, radiotherapy, or transarterial radioembolization) or systemic therapy (for those ineligible for locoregional treatments or who do not benefit from TACE). The recent emergence of novel immunotherapies such as immune checkpoint inhibitors has begun to change the landscape of systemic HCC treatment in the Gulf. The combination of atezolizumab and bevacizumab is currently the preferred first-line therapy in patients not at risk of bleeding. Additionally, the HIMALAYA trial has demonstrated the superiority of the durvalumab plus tremelimumab combination (STRIDE regimen) therapy in efficacy and safety compared with sorafenib in patients with unresectable HCC. However, there is a lack of data on post-progression treatment after first-line therapy with either atezolizumab plus bevacizumab or durvalumab plus tremelimumab regimens, highlighting the need for better-designed studies for improved management of patients with unresectable HCC in the Gulf region.

16 March 2022
Verified
Book Chapter
Open access
PDF file
AAAhmad Alhuraiji
Ahmad Alhuraiji
JAJinan Abdullah
Jinan Abdullah
BABader O. Almutairi
Bader O. Almutairi
JAJasem Albarrak
Jasem Albarrak
The State of Kuwait is an active member of the Arabian Gulf Cooperation Council (GCC). Cancer care has taken its leadership for more than 50 years by establishing the first cancer center in the region called Kuwait Cancer Control Center (KCCC). The healthcare system in Kuwait has rapidly evolved over the last two decades with more specialized healthcare professionals and dedicated services entering the system. This chapter focuses on different aspects of cancer care in Kuwait, starting from demographic and epidemiological data, the set-up of the healthcare system in Kuwait with more focus on the multidisciplinary cancer care ending up with future directions.

28 November 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
MAMaryam Alrashid
Maryam Alrashid
AAAhmad Al-Serri
Ahmad Al-Serri
RHRubina F. Hussain
Rubina F. Hussain
SASuzanne Albustan
Suzanne Albustan
JAJasem Albarrak
Jasem Albarrak
Early detection of colorectal cancer (CRC) increases the 5-year survival rate by 90%; therefore, non-invasive biomarkers such as measurable circulating proteins for early detection and prognosis are crucial. Insulin-like growth factor-1 (IGF-1) is involved in the regulation of cell proliferation and apoptosis. IGF binding proteins (IGFBPs) bind and inhibit the activity of IGF-1. It was inconsistently reported that high IGF-1 and IGFBP-2 and low IGFBP-3 circulating levels are associated with high cancer risk, poor prognosis, and tumor metastasis in several cancers. A total of 175 patients with CRC and 429 controls were enrolled in this study. We genotyped for IGF-1 rs35767 and rs6214 gene polymorphisms and assessed their association with circulating levels of IGF-1 and/or the risk for CRC. We also determined plasma levels of IGF-1, IGFBP-2, and IGFBP-3. Neither rs35767 nor rs2614 were associated with cancer risk or IGF-1 levels in our study cohort. IGF-1 and IGFBP-3 levels were higher in controls than in patients, whereas IGFBP-2 was higher in patients than in controls. Only IGFBP-2 was associated with increased tumor grade but not stage. Therefore, IGF-1, IGFBP-2, and IGFBP-3 may be useful as early detection and prognostic biomarkers in CRC.

Verified
Journal Article
Open access
PDF file
SASara Waleed Alsrayea
Sara Waleed Alsrayea
MAMaryam Alrashid
Maryam Alrashid
NBNasmah K. Bastaki
Nasmah K. Bastaki
JAJasem Albarrak
Jasem Albarrak
Colorectal cancer (CRC) and non-Hodgkin lymphoma (NHL) are among the most prevalent cancer types globally by incidence and mortality. Both types are influenced differentially by chronic inflammation. Central to this inflammation are inflammatory genes that are meticulously regulated by nuclear factor kappa B (NF-κB) and tumor necrosis factor-α (TNF-α). NF-κB is negatively regulated by IκBα (encoded by NFKBIA), while TNF-α’s actions can be modulated by ghrelin (encoded by GHRL). We investigated four single nucleotide polymorphisms (SNPs) in NFKB1 (rs4648068), NFKBIA (rs2233406), TNF-α (rs1800629), and GHRL (rs1629816) as biomarkers for CRC and NHL risk in a cohort of Kuwaiti individuals. DNA samples from patients and controls were collected and genotyped for all SNPs, and their association with CRC or NHL risk was assessed. While rs4648068 showed a modest association with increased CRC risk, it had no significant impact on NHL risk. Conversely, rs2233406 increased NHL risk without affecting CRC risk. Interestingly, while rs1800629 showed a protective effect against NHL, it showed an increased risk for CRC. Finally, rs1629816 was associated with greater NHL but not CRC risk. Our findings suggests that variations of these inflammatory genes may be useful indicators for predicting cancer risk but might have unpredictable effects on cancer susceptibility, depending on the cancer type.